These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 7911039)

  • 1. Chronic haloperidol: neural correlates of motor disorders in an invertebrate model.
    Sakharov D; Voronezhskaya E; Nezlin L
    Neuroreport; 1994 Feb; 5(6):667-70. PubMed ID: 7911039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional consequences of iron overload in catecholaminergic interactions: the Youdim factor.
    Archer T; Fredriksson A
    Neurochem Res; 2007 Oct; 32(10):1625-39. PubMed ID: 17694434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multitracer assessment of dopamine function after transplantation of embryonic stem cell-derived neural stem cells in a primate model of Parkinson's disease.
    Muramatsu S; Okuno T; Suzuki Y; Nakayama T; Kakiuchi T; Takino N; Iida A; Ono F; Terao K; Inoue N; Nakano I; Kondo Y; Tsukada H
    Synapse; 2009 Jul; 63(7):541-8. PubMed ID: 19253400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
    Brown AR; Hu B; Antle MC; Teskey GC
    Exp Neurol; 2009 Nov; 220(1):162-70. PubMed ID: 19703443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Some behavioural effects of carbamazepine - comparison with haloperidol.
    Nowakowska E; Kus K; Czubak A; Glowacka D; Matschay A
    J Physiol Pharmacol; 2007 Jun; 58(2):253-64. PubMed ID: 17622695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in understanding L-DOPA-induced dyskinesia.
    Cenci MA; Lindgren HS
    Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
    Hornykiewicz O
    Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease.
    Hahn M; Timmer M; Nikkhah G
    J Neurosci Res; 2009 Jul; 87(9):2006-19. PubMed ID: 19235889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic intermittent L-DOPA treatment induces changes in dopamine release.
    Lundblad M; af Bjerkén S; Cenci MA; Pomerleau F; Gerhardt GA; Strömberg I
    J Neurochem; 2009 Feb; 108(4):998-1008. PubMed ID: 19196428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.